Patents by Inventor Saad Kenderian

Saad Kenderian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF CANCER USING A CD123 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20230220090
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
    Type: Application
    Filed: December 30, 2022
    Publication date: July 13, 2023
    Inventors: Jennifer Brogdon, Saar Gill, David Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
  • Treatment of cancer using a CD123 chimeric antigen receptor
    Patent number: 11591404
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: February 28, 2023
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Saar Gill, David Jonathan Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
  • TREATMENT OF CANCER USING A CD123 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20210002377
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
    Type: Application
    Filed: May 27, 2020
    Publication date: January 7, 2021
    Inventors: Jennifer Brogdon, Saar Gill, David Jonathan Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
  • TREATMENT OF CANCER USING A CLL-1 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20200215171
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.
    Type: Application
    Filed: December 27, 2019
    Publication date: July 9, 2020
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, Saar Gill, David Jonathan Glass, Julia Jascur, Saad Kenderian, Joan Mannick, Michael C. Milone, Leon Murphy, Celeste Richardson, Reshma Singh, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang
  • Treatment of cancer using a CD123 chimeric antigen receptor
    Patent number: 10703819
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: July 7, 2020
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Jennifer Brogdon, Saar Gill, David Jonathan Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
  • Treatment of cancer using a CLL-1 chimeric antigen receptor
    Patent number: 10568947
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: February 25, 2020
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, Saar Gill, David Glass, Julia Jascur, Saad Kenderian, Joan Mannick, Michael C. Milone, Leon Murphy, Celeste Richardson, Reshma Singh, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang
  • TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20190388471
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
    Type: Application
    Filed: June 7, 2019
    Publication date: December 26, 2019
    Applicants: Novartis AG, The Trustees of the University of Pennsylvania, The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, David L. Porter, Marcela Maus, Mariusz Wasik, Saar Gill, Joseph A. Fraietta, Marco Ruella, John Byrd, Jason Dubovsky, Amy Johnson, Natarajan Muthusamy, Saad Kenderian, Joan Mannick, David Jonathan Glass, Leon Murphy, Jennifer Brogdon, William Raj Sellers
  • TREATMENT AND PREVENTION OF CYTOKINE RELEASE SYNDROME USING A CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH A KINASE INHIBITOR
    Publication number: 20190336504
    Abstract: The disclosure provides compositions and methods for treating diseases associated with expression of an antigen or for treating or prevent cytokine release syndrome, e.g., by administering a CAR therapy with a kinase inhibitor, e.g., JAK-STAT inhibitor and/or BTK inhibitor.
    Type: Application
    Filed: July 14, 2017
    Publication date: November 7, 2019
    Inventors: Saar Gill, Saad Kenderian, Marco Ruella
  • Treatment of cancer using anti-CD19 Chimeric Antigen Receptor
    Patent number: 10357514
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: July 23, 2019
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Carl H. June, David L. Porter, Marcela Maus, Mariusz Wasik, Saar Gill, Joseph Fraietta, Marco Ruella, John Byrd, Jason Dubovsky, Amy Johnson, Natarajan Muthusamy, Saad Kenderian, Joan Mannick, David Glass, Leon Murphy, Jennifer Brogdon, William Raj Sellers
  • TREATMENT OF CANCER USING A CD123 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20180312595
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
    Type: Application
    Filed: October 6, 2017
    Publication date: November 1, 2018
    Applicants: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Saar Gill, David Jonathan Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
  • Treatment of cancer using a CD123 chimeric antigen receptor
    Patent number: 9815901
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: November 14, 2017
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Saar Gill, David Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
  • TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20160096892
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.
    Type: Application
    Filed: July 21, 2015
    Publication date: April 7, 2016
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, NOVARTIS AG
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, Saar Gill, David Glass, Thomas Huber, Julia Jascur, Saad Kenderian, Joan Mannick, Michael C. Milone, Leon Murphy, Celeste Richardson, Reshma Singh, Huijuan Song, Qilong Wu, Jiquan Zhang
  • TREATMENT OF CANCER USING A CD123 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20160068601
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
    Type: Application
    Filed: August 19, 2015
    Publication date: March 10, 2016
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, NOVARTIS AG
    Inventors: Jennifer Brogdon, Saar Gill, David Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
  • TREATMENT OF CANCER USING A CLL-1 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20160051651
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.
    Type: Application
    Filed: July 21, 2015
    Publication date: February 25, 2016
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, NOVARTIS AG
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, Saar Gill, David Glass, Julia Jascur, Saad Kenderian, Joan Mannick, Michael C. Milone, Leon Murphy, Celeste Richardson, Reshma Singh, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang
  • TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20150283178
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
    Type: Application
    Filed: April 7, 2015
    Publication date: October 8, 2015
    Inventors: Carl H. June, David L. Porter, Marcela Maus, Mariusz Wasik, Saar Gill, Joseph Fraietta, Marco Ruella, John Byrd, Jason Dubovsky, Amy Johnson, Natarajan Muthusamy, Saad Kenderian, Joan Mannick, David Glass, Leon Murphy, Jennifer Brogdon, William Raj Sellers